Creative medical technology holdings announces irb approval for fda cleared phase 1/2 clinical trial of stemspine® using allostem™ ("celz-201-ddt") novel cell therapy to treat chronic lower back pain

Company reaches next clinical trial milestone for the intramuscular treatment of chronic lower back pain with the first novel allogenic cellular therapy in the united states phoenix , oct. 10, 2023 /prnewswire/ -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that it has received institutional review board ("irb") approval to proceed with its clinical trial for the treatment of chronic lower back pain with its stemspine® procedure using allostem™ ("celz-201-ddt") cell therapy. the receipt of irb approval is a necessary step that will allow creative medical technology to move forward with recruitment of its recently fda approved phase 1 /2 randomized, double blind, placebo controlled clinical trial to evaluate the safety, efficacy, and tolerability of celz-201-ddt.
CELZ Ratings Summary
CELZ Quant Ranking